It's early days for development of the tumor mutational burden (TMB) as a way of guiding immuno-oncology (IO) drugs, but if the recent American Society of Clinical Oncology meeting is any indication, specialists are warming to the biomarker and sponsors say they are fully committed to further development.
Tumor mutation burden refers to the number of mutations in tumor cells, with higher levels of damage meaning there is a greater likelihood of response to treatment
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?